News

SHERIDAN, WYOMING - December 11, 2025 - Terns Pharmaceuticals is rapidly emerging as a serious contender in chronic myeloid leukemia (CML), after early clinical data for its allosteric BCR/ABL1 inhibitor TERN-701 more than doubled response rates seen with Novartis' approved STAMP inhibitor Scemblix in comparable settings and sent the biotech's share price sharply higher.

Best-in-Disease Early Efficacy Raises the Bar in CML

At the American Society of Hematology (ASH) annual meeting, Terns reported Phase I data from the CARDINAL trial in previously treated CML patients, with 38 participants evaluable for efficacy. TERN-701 achieved a major molecular response (MMR) rate of 75% at week 24, with 64% of patients reaching MMR overall in the dataset presented. The investigational agent also supported simple once-daily dosing without a food effect, improving convenience relative to many existing tyrosine kinase inhibitor (TKI) regimens.

SHERIDAN, WYOMING - December 11, 2025 - Mercedes-Benz is expanding its sustainability playbook with "Tomorrow XX", a cross-portfolio technology program designed to decarbonize vehicle components, scale circular materials and turn end-of-life cars into a strategic raw-materials source. For OEMs, suppliers and material innovators, the initiative signals how one of the world's leading premium automotive brands plans to industrialize low-carbon, circular design across its global lineup.

Holistic sustainability roadmap across the Mercedes-Benz portfolio

Tomorrow XX extends the holistic, multi-disciplinary approach first showcased in the VISION EQXX and CONCEPT AMG GT XX to the entire product portfolio, across all drivetrains. From the earliest design stages through to end-of-life, every component and material is being scrutinized for CO₂ impact, resource intensity and recyclability.

SHERIDAN, WYOMING - December 10, 2025 - Pfizer Inc. is expanding its cardiometabolic ambitions through an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical, to develop, manufacture and commercialize YP05002, an oral GLP-1 receptor agonist currently in Phase 1 for chronic weight management. The deal strengthens Pfizer's position in the fast-moving obesity field and adds a differentiated small-molecule asset to its portfolio of metabolic disease candidates.

Strategic Bet on Small-Molecule GLP-1 in Obesity

Under the agreement, China-based YaoPharma will complete an ongoing Phase 1 study of YP05002 before transferring global development and commercialization rights to Pfizer. For Pfizer, the asset fits neatly into a strategy that aims to pair novel mechanisms with scalable, oral delivery formats for obesity and adjacent cardiometabolic conditions.

SHERIDAN, WYOMING - December 10, 2025 - Pfizer Inc. is setting the stage for its next financial chapter with an analyst conference call and webcast on December 16, 2025, where the U.S.-based biopharmaceutical leader will present full-year 2026 financial guidance to investors and the broader market. The event underscores how large pharma companies use structured guidance cycles to frame expectations around revenue, R&D investment, pipeline execution and capital allocation.

Anchoring Investor Expectations with 2026 Guidance

Pfizer will host the live call with investment analysts at 8:00 a.m. EST on Tuesday, December 16, 2025, with a simultaneous webcast for global stakeholders. The primary objective is to provide formal full-year 2026 financial guidance, giving clarity on topline trends, margin expectations, R&D spending and the company's capital deployment priorities.

SHERIDAN, WYOMING - December 10, 2025 - Yupp Video Services (YVS), the B2B technology arm of YuppTV, is stepping up its role as a white-label OTT backbone provider by delivering a full-stack platform overhaul for Chaupal, one of India's fastest-growing regional streaming services for Punjabi, Haryanvi and Bhojpuri content. The partnership is designed to harden reliability, boost performance and modernize user experience as Chaupal enters its next aggressive growth phase.

Full Technology Replatforming for High-Growth Regional OTT

After three years of rapid subscriber expansion, Chaupal reached the limits of its existing technology stack and needed an infrastructure built for scale, multi-device reach and operational resilience. Yupp Video Services responded with a fully custom instance of its OTT platform tailored to Chaupal's regional content strategy and monetization model.

SHERIDAN, WYOMING - December 10, 2025 - TCL SunPower Global is expanding its European residential solar strategy with a new fully integrated home energy storage system designed to work natively with SunPower solar panels and the SunPower app, giving installers and homeowners a single-vendor ecosystem for generation, storage and digital energy management.

From Standalone Batteries to a Connected Home Energy Ecosystem

The new SunPower home energy storage system is positioned as the core of a connected domestic energy ecosystem rather than a standalone battery. By combining PV generation, storage and load control through one brand, one account and one app, TCL SunPower aims to simplify deployment and post-sale support for its installer partners while helping homeowners maximize self-consumption and energy independence.

SHERIDAN, WYOMING - December 10, 2025 - Implantica is strengthening its European market expansion for RefluxStop®, announcing that Florence's renowned Careggi University Hospital has performed its first procedure with the implantable device for gastroesophageal reflux disease (GERD), adding another high-profile reference center to the therapy's growing footprint.

Careggi University Hospital Becomes a Flagship Center for GERD Innovation

The first RefluxStop® implantation at Careggi University Hospital was carried out by Dr. Paolo Prosperi, Chief of Emergency Surgery, assisted by Dr. Alessio Giordano. As part of the University of Florence, Careggi is one of Italy's most respected academic medical centers and a key reference institution for advanced surgical technologies.

SHERIDAN, WYOMING - December 10, 2025 - Husqvarna Group is sharpening its long-term strategy to deliver profitable growth, unveiling new 2030 financial and sustainability targets and a transformational cost-out program as it positions its global outdoor equipment and robotics portfolio for higher margins and capital efficiency.

New 2030 Strategy Anchored in Portfolio Focus and Operational Excellence

At its Capital Markets Day in Stockholm, Husqvarna Group's leadership team briefed institutional investors, analysts and financial media on the next strategy period to 2030. The company will focus on strategic portfolio management, operational excellence and full leverage of its aftermarket offering across its core manufacturing and industry segments.

SHERIDAN, WYOMING - December 10, 2025 - SK Chemicals is moving to secure full control over its circular plastics value chain by vertically integrating feedstock sourcing through a new joint venture and Feedstock Innovation Center (FIC) in China, positioning its depolymerization-based chemical recycling business for stronger cost competitiveness and supply stability across Asia-Pacific.

From Depolymerization Pioneer to Fully Integrated Circular Plastics Player

SK Chemicals has signed a joint venture agreement with Shaanxi-based recycler Kelinle to build the Feedstock Innovation Center, a dedicated facility for processing waste plastics into recycled raw materials. Located on an idle 13,200 m² site in Weinan, Shaanxi Province, the FIC will convert end-of-life plastics into PET pellets that feed SK Chemicals' depolymerization process.

SHERIDAN, WYOMING - December 10, 2025 - VisIC Technologies has raised $26 million in a Round B financing that positions its Gallium Nitride (GaN) power devices at the center of the next wave of electric vehicle (EV) drivetrain innovation for global automotive and mobility markets. Led by a global semiconductor leader with Hyundai Motor Company and Kia (HKMC) joining as strategic investor, the funding will help VisIC industrialize its D³GaN™ platform for high-volume traction inverters and adjacent high-voltage applications.

GaN Steps Forward as EV OEMs Push Beyond Silicon and SiC